Thermo Fisher Scientific (TMO 10.46%), a leader in life sciences tools and diagnostics, reported its second quarter 2025 results on July 23, 2025. The company outpaced expectations on both revenue and non-GAAP EPS, delivering $10.85 billion in revenue and $5.36 in non-GAAP EPS versus analyst estimates of $10.68 billion and $5.23, respectively. While revenue climbed by 3.0% from the prior year, operating margins tightened and free cash flow fell sharply, signaling growing pressures behind continued growth. O ...

Key Takeaways TMO posted Q2 EPS of $5.36 and revenues of $10.85B, both beating the Zacks Consensus Estimate. TMO's Life Sciences and Biopharma Services drove growth, offsetting Analytical Instruments weakness. New product launches like Orbitrap systems and DynaDrive bioreactors boosted TMO's commercial performance.Thermo Fisher Scientific Inc.'s (TMO) second-quarter 2025 adjusted earnings per share (EPS) of $5.36 beat the Zacks Consensus Estimate by 2.7%. However, the figure decreased 0.2% year over year. ...